

# Person—type of opioid pharmacotherapy treatment, code N

Exported from METEOR (AIHW's Metadata Online Registry)

© Australian Institute of Health and Welfare 2024

This product, excluding the AIHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 4.0 (CC BY 4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website's material but must attribute the AIHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at <https://creativecommons.org/licenses/by/4.0/>.

Enquiries relating to copyright should be addressed to [info@aihw.gov.au](mailto:info@aihw.gov.au).

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at [meteor@aihw.gov.au](mailto:meteor@aihw.gov.au).

# Person—type of opioid pharmacotherapy treatment, code N

## Identifying and definitional attributes

<b>Metadata item type:</b>	Data Element
<b>Short name:</b>	Type of opioid pharmacotherapy treatment
<b>METEOR identifier:</b>	696815
<b>Registration status:</b>	<a href="#">Health</a> , Qualified 06/07/2023
<b>Definition:</b>	The type of opioid pharmacotherapy administered to a person, as represented by a code.
<b>Data Element Concept:</b>	<a href="#">Person—type of opioid pharmacotherapy treatment</a>
<b>Value Domain:</b>	<a href="#">Type of opioid pharmacotherapy treatment code N</a>

## Value domain attributes

## Representational attributes

<b>Representation class:</b>	Code
<b>Data type:</b>	Number
<b>Format:</b>	N
<b>Maximum character length:</b>	1

	Value	Meaning
<b>Permissible values:</b>	1	Methadone
	2	Buprenorphine-naloxone
	3	Buprenorphine long-acting injection
	4	Buprenorphine
	5	Naltrexone

## Collection and usage attributes

<b>Guide for use:</b>	<p>CODE 1 Methadone</p> <p>Includes treatment programs whereby the administered opioid substitute is methadone.</p> <p>CODE 2 Buprenorphine-naloxone</p> <p>Includes treatment programs whereby the administered opioid substitute is buprenorphine-naloxone such as Suboxone.</p> <p>CODE 3 Buprenorphine long-acting injection</p> <p>Includes treatment programs whereby the administered opioid substitute is buprenorphine long-acting injection such as Buvidal, Sublocade.</p> <p>CODE 4 Buprenorphine</p> <p>Includes treatment programs whereby the administered opioid substitute is buprenorphine such as Subutex, Probuphine.</p> <p>CODE 5 Naltrexone</p> <p>Includes treatment programs whereby the administered opioid substitute is naltrexone.</p>
<b>Comments:</b>	Opiate substitution programs use a long-acting synthetic opiate medication, usually methadone or levo-alpha acetyl methadol, administered orally for a sustained period at a dosage sufficient to prevent opiate withdrawal, block the effects of illicit opiate use and decrease opiate craving.

## Source and reference attributes

<b>Submitting organisation:</b>	Australian Institute of Health and Welfare
<b>Reference documents:</b>	Australian Institute of Health and Welfare (2022) <a href="#">National Opioid Pharmacotherapy Statistics Annual Data collection</a> , AIHW, Australian Government, accessed 21 September 2022.

## Data element attributes

### Collection and usage attributes

<b>Guide for use:</b>	This data element should be used in conjunction with the data elements: <a href="#">Person—previous opioid pharmacotherapy treatment program indicator, prisoner health yes/no/unknown code N</a> and <a href="#">Person—current opioid pharmacotherapy treatment program indicator, prisoner health yes/no/unknown code N</a> to provide information on a person's history of opioid pharmacotherapy treatment.
-----------------------	--

## Source and reference attributes

<b>Submitting organisation:</b>	Australian Institute of Health and Welfare
<b>Reference documents:</b>	<p>Dolan KA, Hall W &amp; Wodak A 1996. Methadone maintenance reduces injecting in prison. British Medical Journal 312:1162.</p> <p>Australian Institute of Health and Welfare (2022) <a href="#">National Opioid Pharmacotherapy Statistics Annual Data collection</a>, AIHW, Australian Government, accessed 21 September 2022.</p>

## Relational attributes

**Related metadata references:**

Supersedes [Person—type of opioid pharmacotherapy treatment, code N](#)  
[Health](#), Standard 28/04/2016

See also [Person—current opioid pharmacotherapy treatment program indicator, prisoner health yes/no/unknown code N](#)  
[Health](#), Qualified 06/07/2023

See also [Person—previous opioid pharmacotherapy treatment program indicator, prisoner health yes/no/unknown code N](#)  
[Health](#), Qualified 06/07/2023

See also [Prison discharger—opioid substitution program continuation on release indicator, prisoner health yes/no/unknown code N](#)  
[Health](#), Standard 28/04/2016

**Implementation in Data Set Specifications:**

[Opioid pharmacotherapy treatment cluster \(entrant\)](#)  
[Health](#), Qualified 06/07/2023

***Conditional obligation:***

Conditional on the respondent indicating that they are currently on, or have been on a pharmacotherapy for opioid dependence.

[Opioid pharmacotherapy treatment program cluster \(dischargee\)](#)  
[Health](#), Qualified 06/07/2023